Joint replacement surgeons routinely see patients whose knee or hip pain is made worse by excess weight. A question that comes up often in that conversation is whether losing weight with a GLP-1 medication such as semaglutide or tirzepatide can reduce the chance of eventually needing a knee or hip replacement. Two recent cohort studies give a partial, carefully qualified answer.
What the studies actually measured
Both studies are retrospective database analyses, not randomized trials. They compare outcomes in large groups of patients who were already prescribed a GLP-1 receptor agonist against similar patients who were not, using statistical matching to reduce the effect of other differences between the groups. That design can show an association. It cannot prove that the medication caused the difference.
A 2025 study in the Orthopaedic Journal of Sports Medicine followed obese patients in a national health research network and separated them by whether they already had diagnosed hip or knee osteoarthritis. In the group that already had osteoarthritis, GLP-1 use was associated with a lower rate of conversion to total knee replacement (1.4 percent versus 2.1 percent; hazard ratio 0.8, 95 percent confidence interval 0.6 to 0.9) and total hip replacement (1.1 percent versus 2.2 percent; hazard ratio 0.6, 95 percent confidence interval 0.5 to 0.8).
A second study, published in 2026 in Regional Anesthesia and Pain Medicine, used a different large database and looked specifically at adults with existing knee osteoarthritis. One year of exposure to any GLP-1 receptor agonist was associated with a hazard ratio of 0.90 (95 percent confidence interval 0.83 to 0.98) for conversion to knee replacement, an absolute difference of about 2.8 percentage points by eight years of follow-up. Three years of exposure to semaglutide or tirzepatide specifically was associated with a hazard ratio of 0.72 (95 percent confidence interval 0.67 to 0.78), an absolute difference of about 4.7 percentage points by eight years.
Read together, the two studies place the effect, in people who already have knee or hip osteoarthritis, in the range of roughly a 10 to 28 percent relative reduction in the rate of joint replacement, or about 3 to 5 percentage points over several years. That is a real and clinically relevant signal in this population. It is a smaller and more specific finding than a blanket claim that GLP-1 therapy lowers knee replacement risk for everyone.
The finding that complicates the story
The 2025 study also looked at obese patients who did not yet have diagnosed osteoarthritis. In that group, GLP-1 use was associated with a higher rate of being newly diagnosed with knee osteoarthritis and a higher rate of converting to total knee replacement (hazard ratio 2.6, 95 percent confidence interval 1.6 to 4.3) than in matched patients not on a GLP-1 medication.
The authors did not establish why. Possible explanations include patients being started on a GLP-1 medication because of joint symptoms that had not yet been formally diagnosed, more frequent medical contact leading to more diagnoses, or genuine biological effects that differ by disease stage. Whatever the explanation, this finding means the honest summary is narrower than "GLP-1 prevents knee replacement." The signal for benefit is specific to people who already have osteoarthritis and are trying to avoid its progression, not to healthy joints in general.
Why weight matters mechanically
Independent of these two cohort studies, the mechanical relationship between body weight and knee joint load is well established: every step loads the knee with a multiple of body weight, so weight lost reduces the force the joint absorbs with each stride. Semaglutide and tirzepatide produce substantially more weight loss than diet and exercise alone typically achieve, which is the mechanical basis for expecting some joint benefit, even though the cohort data above show the picture is more specific than a simple cause and effect.
Who this evidence is most relevant to
The available evidence is most relevant to adults who already have diagnosed knee or hip osteoarthritis, carry excess weight, and want to understand whether a GLP-1 medication might reduce their chance of eventually needing joint replacement. It is not evidence that starting a GLP-1 medication will prevent osteoarthritis from developing in someone with healthy joints, and it is not a substitute for the orthopedic evaluation that determines how advanced a given patient's joint disease already is.
Questions worth bringing to a provider
- Do I already have diagnosed osteoarthritis in this joint, or is this still an open question?
- How advanced is the cartilage loss on imaging, and does that change what weight loss can realistically do for me?
- Would a structured weight loss program, a GLP-1 medication, physical therapy, or some combination fit my situation best?
- What is a reasonable follow-up schedule to track both my weight and my joint symptoms over time?
Where Truthe fits
Truthe was founded by orthopedic surgeons and supports patients through the nutrition side of weight management and surgical recovery. If you and a licensed provider decide that a GLP-1 medication belongs in your plan, the Truthe Rx LEAN program offers semaglutide or tirzepatide to adults, and the Truthe Rx MICRODOSING program offers a lower-dose approach. Truthe does not prescribe, and an independent licensed provider decides whether a prescription is appropriate for you.
Disclaimer: This content is for educational purposes only and is not medical advice. Talk with an orthopedic surgeon and a licensed healthcare provider about your situation.
Sources
- Orthopaedic Journal of Sports Medicine. The impact of contemporary glucagon-like peptide-1 receptor agonists on the onset, severity, and conversion to arthroplasty in hip and knee osteoarthritis. 2025. pubmed.ncbi.nlm.nih.gov/39811151
- Carter V, et al. Glucagon-like peptide 1 receptor agonist use and risk of arthroplasty for knee osteoarthritis: retrospective database analysis. Reg Anesth Pain Med. 2026. pubmed.ncbi.nlm.nih.gov/42229941
Ready to Start?
Explore personalized treatment plans designed around your goals — backed by licensed providers and premium compounding pharmacies.
